Integrated Continuous Biomanufacturing III

Memo

Continuous bioprocessing has the inherent advantage of higher productivity which can facilitate implementation of small process trains, resulting in cost-effective, lean, and agile manufacturing facilities. Impressive technological advances to enable continuous bioprocessing have been made in the recent past and have been discussed at Integrated Continuous Biomanufacturing (ICB) I (2013) and II (2015) conferences. The range of topics that were discussed illustrates the active and enthusiastic engagement of biopharmaceutical industry, academia, and regulatory authorities.



ICB II (2017) aims to build on the strong momentum generated at the previous two conferences in the series. The agenda will include progress on the state-of-the-art technologies and emerging trends in continuous upstream, downstream, and drug product unit operations. Case studies for the implementation of continuous platforms will also be discussed, spanning scale-down mimics and control strategies through to end-to-end continuous processes and facility designs.



The ICB conference will bring together leading scientists and engineers from academic, industry and regulatory authorities who are actively engaged in integrated continuous bioprocessing. We look forward to welcoming you to Albufeira, Portugal, and debating how industrialized our sector can become and the scenarios where continuous platforms will better serve our needs.